Spyre Therapeutics Current Valuation vs. Revenue
| SYRE Stock | 24.12 0.20 0.84% |
For Spyre Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Spyre Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Spyre Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Spyre Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Spyre Therapeutics over time as well as its relative position and ranking within its peers.
Spyre |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Spyre Therapeutics Revenue vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Spyre Therapeutics's current stock value. Our valuation model uses many indicators to compare Spyre Therapeutics value to that of its competitors to determine the firm's financial worth. Spyre Therapeutics is rated third in current valuation category among its peers. It is rated fourth in revenue category among its peers . The ratio of Current Valuation to Revenue for Spyre Therapeutics is about 1,424 . At present, Spyre Therapeutics' Total Revenue is projected to decrease significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Spyre Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Spyre Current Valuation vs. Competition
Spyre Therapeutics is rated third in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 6.21 Billion. Spyre Therapeutics totals roughly 1.26 Billion in current valuation claiming about 20% of equities under Health Care industry.
Spyre Revenue vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Spyre Therapeutics |
| = | 1.26 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Spyre Therapeutics |
| = | 886 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Spyre Revenue vs Competition
Spyre Therapeutics is rated fourth in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 297.71 Million. Spyre Therapeutics adds roughly 886,000 in revenue claiming only tiny portion of equities under Health Care industry.
Spyre Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Spyre Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Spyre Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Spyre Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Spyre Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 302 K | 317.1 K | |
| Operating Income | -242.3 M | -230.2 M | |
| Income Before Tax | -338.8 M | -321.9 M | |
| Total Other Income Expense Net | -96.5 M | -91.7 M | |
| Net Loss | -338.8 M | -321.9 M | |
| Net Interest Income | 6.1 M | 6.5 M | |
| Interest Income | 6.1 M | 6.5 M | |
| Net Loss | -338.8 M | -321.9 M | |
| Income Tax Expense | -26 K | -27.3 K | |
| Net Loss | (49.12) | (51.58) | |
| Income Quality | 0.29 | 0.28 | |
| Net Income Per E B T | 1.00 | 1.10 |
Spyre Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Spyre Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Spyre Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Spyre Therapeutics' important profitability drivers and their relationship over time.
Use Spyre Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spyre Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will appreciate offsetting losses from the drop in the long position's value.Spyre Therapeutics Pair Trading
Spyre Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Spyre Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spyre Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spyre Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spyre Therapeutics to buy it.
The correlation of Spyre Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spyre Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spyre Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spyre Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Spyre Therapeutics position
In addition to having Spyre Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Asset Allocation ETFs Thematic Idea Now
Asset Allocation ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Asset Allocation ETFs theme has 145 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Asset Allocation ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
To fully project Spyre Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Spyre Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Spyre Therapeutics' income statement, its balance sheet, and the statement of cash flows.